Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GLB1 | P16278 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 5/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958961 | 1.00 | GBA1 (0.47) | GBA1PYGLGBA2GAAGLB1 | |
| Bromide SCHEMBL1941630 | 0.98 | GBA1 (0.46) | GBA1PYGLGBA2GAAGLB1 | |
| Bromide SCHEMBL5282167 | 0.98 | GBA1 (0.46) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL6042903 | 0.85 | GBA1 (0.46) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL6041817 | 0.84 | ESR2 (0.42) | GBA1GAAGLB1MGAMESR1 | |
| SCHEMBL6041814 | 0.84 | ESR2 (0.42) | GBA1GAAGLB1MGAMESR1 | |
| SCHEMBL6955872 | 0.81 | GBA1 (0.43) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL6042465 | 0.77 | KDM4E (0.42) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL6626149 | 0.72 | REN (0.42) | GBA1ESR1ESR2CYP2C9 | |
| SCHEMBL12558167 | 0.71 | ESR2 (0.37) | GBA1GAAMGAMESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | HEROLD PETER (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-1863763-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2006103275-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | GBA1 106/4885PYGL 1679/4885GBA2 293/4885 |
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | GBA1 1639/4885PYGL 1515/4885GBA2 2253/4885 |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGTR1, AGTR2 | GBA1 1611/4885PYGL 1484/4885GBA2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.